Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 1/20 | 0.36 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.33 |
| ▸ | HTR2C | P28335 | 8/20 | 0.33 |
| ▸ | HTR2A | P28223 | 5/20 | 0.33 |
| ▸ | HTR2B | P41595 | 4/20 | 0.33 |
| ▸ | GSK3B | P49841 | 2/20 | 0.32 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.30 |
| ▸ | PARP11 | Q9NR21 | 1/20 | 0.30 |
| ▸ | IDO1 | P14902 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30060743 | 1.00 | KCNH2 (0.36) | KCNH2ITGA2BHTR2CHTR2AHTR2B | |
| SCHEMBL19995394 | 1.00 | KCNH2 (0.36) | KCNH2ITGA2BHTR2CHTR2AHTR2B | |
| SCHEMBL21853819 | 1.00 | KCNH2 (0.36) | KCNH2ITGA2BHTR2CHTR2AHTR2B | |
| SCHEMBL22551027 | 0.87 | GSK3B (0.38) | HTR2CHTR2AHTR2BGSK3BIDO1 | |
| SCHEMBL21853840 | 0.87 | GSK3B (0.38) | HTR2CHTR2AHTR2BGSK3BIDO1 | |
| SCHEMBL19995187 | 0.86 | GSK3B (0.42) | KCNH2ITGA2BHTR2CHTR2AHTR2B | |
| SCHEMBL19995271 | 0.86 | GSK3B (0.42) | KCNH2ITGA2BHTR2CHTR2AHTR2B | |
| SCHEMBL19995211 | 0.86 | GSK3B (0.42) | KCNH2ITGA2BHTR2CHTR2AHTR2B | |
| SCHEMBL22551022 | 0.85 | KCNH2 (0.36) | KCNH2ITGA2BHTR2CHTR2AHTR2B | |
| SCHEMBL19995209 | 0.85 | KCNH2 (0.36) | KCNH2ITGA2BHTR2CHTR2AHTR2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10919896-B2 | Preparation and uses of pyrimidinone derivatives | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2021-02-16 | — | — | US | claimed |
| EP-3515903-B1 | PREPARATION AND USES OF PYRIMIDINONE DERIVATIVES | CANCER RESEARCH TECH LTD (GB) | 2020-10-21 | — | — | EP | claimed |
| US-20200123157-A1 | PREPARATION AND USES OF PYRIMIDINONE DERIVATIVE | TEVA BRANDED PHARMACEUTICAL PRODUCTS R&D, INC. | 2020-04-23 | — | — | US | claimed |
| US-10919896-B2 | Preparation and uses of pyrimidinone derivatives | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2021-02-16 | — | — | US | disclosed |
| US-10919896-B2 | Preparation and uses of pyrimidinone derivatives | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2021-02-16 | — | — | US | disclosed |
| EP-3515903-B1 | PREPARATION AND USES OF PYRIMIDINONE DERIVATIVES | CANCER RESEARCH TECH LTD (GB) | 2020-10-21 | — | — | EP | disclosed |
| EP-3515903-B1 | PREPARATION AND USES OF PYRIMIDINONE DERIVATIVES | CANCER RESEARCH TECH LTD (GB) | 2020-10-21 | — | — | EP | disclosed |
| US-20200123157-A1 | PREPARATION AND USES OF PYRIMIDINONE DERIVATIVE | TEVA BRANDED PHARMACEUTICAL PRODUCTS R&D, INC. | 2020-04-23 | — | — | US | disclosed |
| US-20200123157-A1 | PREPARATION AND USES OF PYRIMIDINONE DERIVATIVE | TEVA BRANDED PHARMACEUTICAL PRODUCTS R&D, INC. | 2020-04-23 | — | — | US | disclosed |
| WO-2018055402-A1 | PREPARATION AND USES OF PYRIMIDINONE DERIVATIVES | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2018-03-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10919896-B2 | Preparation and uses of pyrimidinone derivatives | CDC7, CDK7, CDK17 | KCNH2 3921/4885ITGA2B 4453/4885HTR2C 4657/4885 |
| US-20200123157-A1 | PREPARATION AND USES OF PYRIMIDINONE DERIVATIVE | CDC7, CDK7, CDK17 | KCNH2 3923/4885ITGA2B 4484/4885HTR2C 4650/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.